SLV.WAR Selvita S.A.

Healthcare Biotechnology Warsaw Stock Exchange
16.66 PLN
Close of Oct 29, 2026
16.66 48.00
Market cap
PLN 306M
P/E
-
P/B
0.98x
ROE
-5.4%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is SLV.WAR undervalued?

Graham number

The Graham number of Selvita S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Selvita S.A. fundamental analysis

6 of 21 checks passed

ROE 0/2

Low return on equity (-5.4%), below 10%.

ROA 1/1

Return on assets (-2.9%) is above the industry median (-18.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (113.3%) is above the 5-year average (-47.9% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (113.3%) is above the industry median (2.6%).

Revenue Growth 0/2

Revenue shrank 3.6% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (54.4%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Cash covers 2.7 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (1.0x) is below the industry median (3.6x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Selvita S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Selvita S.A.

Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, mo…

Full company profile